IPO

News

Anthropic sets out its biopharma ambitions in IPO doc

Anthropic says it is working with nine of the top 10 pharma groups in its IPO prospectus, which also reiterates AI's "existential risks to humanity."

News

RNAi biotech City hauls in $200m in upsized IPO

City Therapeutics has finalised its IPO, raising $200 million for a pipeline of RNA interference therapies headed by a novel anticoagulant.

News

AI in drug discovery & development: News watch, October 2026

Recent news in biopharma AI include a $1.5bn partnership between AstraZeneca and insitro, plus news from Iambic, DaltonTx, NVIDIA, and Chai Discovery.

News

Bambusa, Aspen, and Tang added to IPO pipeline

2026's sizeable haul of IPOs shows no signs of letting up, with three more biotechs – Bambusa, Aspen, and blank cheque firm Tang – joining the queue.

News

Iambic prices its IPO, seeking to raise up to $160m

AI-powered drug discovery company Iambic Therapeutics has announced the terms of its Nasdaq IPO, pitching at a valuation of more than $800m.

News

Iambic files IPO after signing up AbbVie as new partner

In the space of a day, Iambic has filed an IPO, released the latest version of its AI platform, and signed a multi-year alliance with AbbVie.

Anthropic sets out its biopharma ambitions in IPO doc

RNAi biotech City hauls in $200m in upsized IPO

AI in drug discovery & development: News watch, October 2026

Bambusa, Aspen, and Tang added to IPO pipeline

Iambic prices its IPO, seeking to raise up to $160m

Iambic files IPO after signing up AbbVie as new partner

US gives $99m for Ebola jab project, as cases spread in Afri...

Discover a new era of healthcare panel engagement: Grounded ...

IPO

Editor's Picks